Biologics Market (By Source: Microbial, Mammalian, Others; By Product: MABs, Vaccines, Antisense, RNAi & Molecular Therapy, Recombinant Proteins, Others; By Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others; By Manufacturing: Outsourced, In-house; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Biologics Market 

5.1. COVID-19 Landscape: Biologics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Biologics Market, By Source

8.1. Biologics Market, by Source, 2023-2032

8.1.1. Microbial

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Mammalian

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Biologics Market, By Product

9.1. Biologics Market, by Product, 2023-2032

9.1.1. Monoclonal Antibodies

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Vaccines

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. RecombinantProteins

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Antisense, RNAi & molecular therapy

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Cell Based Therapies

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Biologics Market, By Indication 

10.1. Biologics Market, by Indication, 2023-2032

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Immunological Disorders

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Cardiovascular Disorders

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Hematological Disorders

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Biologics Market, By Manufacturing

11.1. Biologics Market, by Manufacturing, 2023-2032

11.1.1. Outsourced

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. In-house

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Biologics Market, By Distribution Channel

12.1. Biologics Market, by Distribution Channel, 2023-2032

12.1.1. Hospital Pharmacies

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Retail Pharmacies

12.1.2.1. Market Revenue and Forecast (2020-2032)

12.1.3. Online Pharmacies

12.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Biologics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Source (2020-2032)

13.1.2. Market Revenue and Forecast, by Product (2020-2032)

13.1.3. Market Revenue and Forecast, by Indication (2020-2032)

13.1.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.1.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Source (2020-2032)

13.1.6.2. Market Revenue and Forecast, by Product (2020-2032)

13.1.6.3. Market Revenue and Forecast, by Indication (2020-2032)

13.1.6.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2020-2032) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Source (2020-2032)

13.1.7.2. Market Revenue and Forecast, by Product (2020-2032)

13.1.7.3. Market Revenue and Forecast, by Indication (2020-2032)

13.1.7.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Source (2020-2032)

13.2.2. Market Revenue and Forecast, by Product (2020-2032)

13.2.3. Market Revenue and Forecast, by Indication (2020-2032)

13.2.4. Market Revenue and Forecast, by Manufacturing (2020-2032) 

13.2.5. Market Revenue and Forecast, by Distribution Channel (2020-2032) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Source (2020-2032)

13.2.6.2. Market Revenue and Forecast, by Product (2020-2032)

13.2.6.3. Market Revenue and Forecast, by Indication (2020-2032)

13.2.7. Market Revenue and Forecast, by Manufacturing (2020-2032) 

13.2.8. Market Revenue and Forecast, by Distribution Channel (2020-2032) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Source (2020-2032)

13.2.9.2. Market Revenue and Forecast, by Product (2020-2032)

13.2.9.3. Market Revenue and Forecast, by Indication (2020-2032)

13.2.10. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.2.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Source (2020-2032)

13.2.12.2. Market Revenue and Forecast, by Product (2020-2032)

13.2.12.3. Market Revenue and Forecast, by Indication (2020-2032)

13.2.12.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.2.13. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Source (2020-2032)

13.2.14.2. Market Revenue and Forecast, by Product (2020-2032)

13.2.14.3. Market Revenue and Forecast, by Indication (2020-2032)

13.2.14.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.2.15. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Source (2020-2032)

13.3.2. Market Revenue and Forecast, by Product (2020-2032)

13.3.3. Market Revenue and Forecast, by Indication (2020-2032)

13.3.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.3.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Source (2020-2032)

13.3.6.2. Market Revenue and Forecast, by Product (2020-2032)

13.3.6.3. Market Revenue and Forecast, by Indication (2020-2032)

13.3.6.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.3.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Source (2020-2032)

13.3.8.2. Market Revenue and Forecast, by Product (2020-2032)

13.3.8.3. Market Revenue and Forecast, by Indication (2020-2032)

13.3.8.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Source (2020-2032)

13.3.10.2. Market Revenue and Forecast, by Product (2020-2032)

13.3.10.3. Market Revenue and Forecast, by Indication (2020-2032)

13.3.10.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Source (2020-2032)

13.3.11.2. Market Revenue and Forecast, by Product (2020-2032)

13.3.11.3. Market Revenue and Forecast, by Indication (2020-2032)

13.3.11.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Source (2020-2032)

13.4.2. Market Revenue and Forecast, by Product (2020-2032)

13.4.3. Market Revenue and Forecast, by Indication (2020-2032)

13.4.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.4.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Source (2020-2032)

13.4.6.2. Market Revenue and Forecast, by Product (2020-2032)

13.4.6.3. Market Revenue and Forecast, by Indication (2020-2032)

13.4.6.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.4.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Source (2020-2032)

13.4.8.2. Market Revenue and Forecast, by Product (2020-2032)

13.4.8.3. Market Revenue and Forecast, by Indication (2020-2032)

13.4.8.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Source (2020-2032)

13.4.10.2. Market Revenue and Forecast, by Product (2020-2032)

13.4.10.3. Market Revenue and Forecast, by Indication (2020-2032)

13.4.10.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Source (2020-2032)

13.4.11.2. Market Revenue and Forecast, by Product (2020-2032)

13.4.11.3. Market Revenue and Forecast, by Indication (2020-2032)

13.4.11.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Source (2020-2032)

13.5.2. Market Revenue and Forecast, by Product (2020-2032)

13.5.3. Market Revenue and Forecast, by Indication (2020-2032)

13.5.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.5.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Source (2020-2032)

13.5.6.2. Market Revenue and Forecast, by Product (2020-2032)

13.5.6.3. Market Revenue and Forecast, by Indication (2020-2032)

13.5.6.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.5.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Source (2020-2032)

13.5.8.2. Market Revenue and Forecast, by Product (2020-2032)

13.5.8.3. Market Revenue and Forecast, by Indication (2020-2032)

13.5.8.4. Market Revenue and Forecast, by Manufacturing (2020-2032)

13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 14. Company Profiles

14.1. Eli Lilly & Company

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Samsung Biologics

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. F Hoffman La Roche

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Celltrion Addgene

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Amgen

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Abbvie Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Sanofi

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Pfizer Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Merck & Co. Inc

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Novo Nordisk A/S

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample